Relay Therapeutics shares are trading are trading higher after HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $18 to $19.
Portfolio Pulse from Benzinga Newsdesk
Relay Therapeutics shares rose after HC Wainwright & Co maintained a Buy rating and increased the price target from $18 to $19.
September 16, 2024 | 11:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Relay Therapeutics shares increased following HC Wainwright & Co's decision to maintain a Buy rating and raise the price target from $18 to $19.
The increase in price target and maintained Buy rating by a reputable firm like HC Wainwright & Co is likely to boost investor confidence, leading to a positive short-term impact on Relay Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100